CYP2C19 and major depressive disorder: Broader PGx testing information involving CYP2C19 or panel-based testing including additional pharmacokinetic and pharmacodynamic markers from patients in the CYP-GUIDES trial could have provided even more targeted therapeutic guidance to ensure rationale prescribing of psychotropics for management of MDD.